Skip to content

Study · Systematic review · n = 7,805 · 2025

6 results

Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes.

Aminorroaya A, Oikonomou EK, Biswas D, Jastreboff AM, Khera R

Journal of the American College of Cardiology30 Mar 2025Cited by 9 (Europe PMC)

PMID40368575 (opens in a new tab)PMCIDPMC12186526 (opens in a new tab)DOI10.1016/j.jacc.2025.03.516 (opens in a new tab)PepBankPUB-40368575
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide reduced the odds of every cardiometabolic abnormality assessed, with reductions of 34% to 96%.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered the odds of each cardiometabolic problem assessed, compared with placebo or standard diabetes drugs.

    Peptide
    Tirzepatide
    Outcome
    DecreaseOdds of individual cardiometabolic abnormalities
    Study

    n = 7,805

    Comparator
    Placebo or standard antihyperglycemic agents
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated · 41.0 weeks (weighted median)As given in this study (human).

    Source sentences

    Summary
    tirzepatide reduced the odds of all cardiometabolic abnormalities, ranging from 34% reduction for the odds of decreased high-density lipoprotein cholesterol (OR: 0.66 [95% CI: 0.52-0.84]) to 96% reduction in the odds of elevated body mass index
    2 context sentences
    Summary · context
    Using an independent, global data-sharing and analytics platform, we performed an individual participant data meta-analysis by pooling data from 7 Phase 3 randomized clinical trials that compared tirzepatide with placebo or standard antihyperglycemic agents in individuals with type 2 diabetes.
    Summary · context
    We included 7,805 participants with a weighted median age of 59 years (Q1-Q3: 51-66 years) and 43.2% women.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide reduced the odds of decreased HDL cholesterol by 34%.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered the odds of low HDL cholesterol compared with placebo or standard diabetes drugs.

    Peptide
    Tirzepatide
    Outcome
    DecreaseOdds of decreased HDL cholesterol
    Study

    n = 7,805

    Comparator
    Placebo or standard antihyperglycemic agents
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 41.0 weeks (weighted median)As given in this study (human).

    Measurements

    odds ratio
    0.66 OR
    decreased HDL cholesterol

    Source sentences

    Summary
    ranging from 34% reduction for the odds of decreased high-density lipoprotein cholesterol (OR: 0.66 [95% CI: 0.52-0.84])
    2 context sentences
    Summary · context
    Using an independent, global data-sharing and analytics platform, we performed an individual participant data meta-analysis by pooling data from 7 Phase 3 randomized clinical trials that compared tirzepatide with placebo or standard antihyperglycemic agents in individuals with type 2 diabetes.
    Summary · context
    We included 7,805 participants with a weighted median age of 59 years (Q1-Q3: 51-66 years) and 43.2% women.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide reduced the odds of elevated body mass index by 96%.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered the odds of having a high body mass index compared with placebo or standard diabetes drugs.

    Peptide
    Tirzepatide
    Outcome
    DecreaseOdds of elevated body mass index
    Study

    n = 7,805

    Comparator
    Placebo or standard antihyperglycemic agents
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 41.0 weeks (weighted median)As given in this study (human).

    Measurements

    odds ratio
    0.04 OR
    elevated body mass index

    Source sentences

    Summary
    to 96% reduction in the odds of elevated body mass index (OR: 0.04 [95% CI:0.02-0.08])
    2 context sentences
    Summary · context
    Using an independent, global data-sharing and analytics platform, we performed an individual participant data meta-analysis by pooling data from 7 Phase 3 randomized clinical trials that compared tirzepatide with placebo or standard antihyperglycemic agents in individuals with type 2 diabetes.
    Summary · context
    We included 7,805 participants with a weighted median age of 59 years (Q1-Q3: 51-66 years) and 43.2% women.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide reduced the odds of metabolic syndrome by 72%.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered the odds of metabolic syndrome compared with placebo or standard diabetes drugs.

    Peptide
    Tirzepatide
    Outcome
    DecreaseOdds of metabolic syndrome
    Study

    n = 7,805

    Comparator
    Placebo or standard antihyperglycemic agents
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated · 41.0 weeks (weighted median)As given in this study (human).

    Measurements

    odds ratio
    0.28 OR
    metabolic syndrome

    Source sentences

    Summary
    and 72% reduction for the odds of MetS (OR: 0.28 [95% CI: 0.24-0.33]).
    2 context sentences
    Summary · context
    Using an independent, global data-sharing and analytics platform, we performed an individual participant data meta-analysis by pooling data from 7 Phase 3 randomized clinical trials that compared tirzepatide with placebo or standard antihyperglycemic agents in individuals with type 2 diabetes.
    Summary · context
    We included 7,805 participants with a weighted median age of 59 years (Q1-Q3: 51-66 years) and 43.2% women.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide's efficacy in resolving metabolic syndrome was higher in those younger than 65 years than in those aged 65 or older.

    In plain wordsIn adults with type 2 diabetes, tirzepatide resolved metabolic syndrome more effectively in people under 65 than in people 65 or older.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMetabolic syndrome resolution by age
    Study

    n = 7,805

    Comparator
    Placebo or standard antihyperglycemic agents
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated · 41.0 weeks (weighted median)As given in this study (human).

    Measurements

    P for interaction
    0.008
    age <65 vs >=65 years

    Source sentences

    Summary
    with higher efficacy in age <65 years vs ≥65 years, and in individuals without vs with baseline use of sodium-glucose cotransporter 2 inhibitors (P for interaction = 0.008
    2 context sentences
    Summary · context
    Using an independent, global data-sharing and analytics platform, we performed an individual participant data meta-analysis by pooling data from 7 Phase 3 randomized clinical trials that compared tirzepatide with placebo or standard antihyperglycemic agents in individuals with type 2 diabetes.
    Summary · context
    We included 7,805 participants with a weighted median age of 59 years (Q1-Q3: 51-66 years) and 43.2% women.
  6. 06HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide's efficacy in resolving metabolic syndrome was higher in those not using sodium-glucose cotransporter 2 inhibitors at baseline.

    In plain wordsIn adults with type 2 diabetes, tirzepatide resolved metabolic syndrome more effectively in people not already taking SGLT2 inhibitors.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMetabolic syndrome resolution by baseline SGLT2 inhibitor use
    Study

    n = 7,805

    Comparator
    Placebo or standard antihyperglycemic agents
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated · 41.0 weeks (weighted median)As given in this study (human).

    Measurements

    P for interaction
    0.009
    without vs with baseline SGLT2 inhibitor use

    Source sentences

    Summary
    and in individuals without vs with baseline use of sodium-glucose cotransporter 2 inhibitors (P for interaction = 0.008 and 0.009, respectively)
    2 context sentences
    Summary · context
    Using an independent, global data-sharing and analytics platform, we performed an individual participant data meta-analysis by pooling data from 7 Phase 3 randomized clinical trials that compared tirzepatide with placebo or standard antihyperglycemic agents in individuals with type 2 diabetes.
    Summary · context
    We included 7,805 participants with a weighted median age of 59 years (Q1-Q3: 51-66 years) and 43.2% women.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.